Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-KPNA2
- Development stage
- Preclinical
- Lead developer
- Shanghai Genechem Co.
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
shRNA-KPNA2 is a research-grade RNA interference (RNAi) tool designed to silence the expression of the KPNA2 (Karyopherin Alpha 2) gene. KPNA2 is a member of the importin alpha family, which plays a critical role in the nucleocytoplasmic transport of proteins, including transcription factors and cell cycle regulators. Overexpression of KPNA2 is associated with poor prognosis and chemoresistance in various malignancies, including multiple myeloma, hepatocellular carcinoma, and oral squamous cell carcinoma. By utilizing a short hairpin RNA sequence typically delivered via lentiviral or plasmid vectors, shRNA-KPNA2 induces sequence-specific degradation of KPNA2 mRNA, thereby inhibiting tumor cell proliferation, migration, and autophagy. In multiple myeloma models, knockdown of KPNA2 has been shown to sensitize cells to bortezomib by modulating the non-canonical NF-κB signaling pathway.
- Other names
- KPNA2 shRNAKPNA-2 shRNAKPNA 2 shRNAsh-KPNA2sh-KPNA-2sh-KPNA 2
02
Targets
KPNA2 (Karyopherin subunit alpha-2)
Beyond the preview
Go deeper on shRNA-KPNA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shRNA-KPNA2.